Abstract Library

#3567 Metastatic mixed VIPoma/PPoma-induced diarrhoea causing renal failure

Introduction: Pancreatic neuroendocrine tumors (pNETs) are rare, but despite better prognosis than other pancreatic tumors, their presentation is often occult. VIPomas are a further subtype secreting vasoactive intestinal peptide (VIP). Associated symptoms are particularly non-specific, with watery diarrhoea and electrolyte disturbance which mimics less sinister pathology. Consequently, this presentation is often overlooked resulting in tumor progression and delayed diagnosis, hindering effective management.

Conference:

Presenting Author: Monaghan A

Authors: Monaghan A, Brown G, Takhar A,

Keywords: Pancreatic Neuroendocrine Tumor, Neuroendocrine Tumor, pNET, Vasoactive Intestinal Peptide, VIPoma, Pancreatic Polypeptide,

#2114 Significance of Biochemical Testing in Pancreatic Neuroendocrine Tumors

Introduction: Pancreatic neuroendocrine tumors (PNETs) are rare tumors that are frequently diagnosed late in the course of the disease. Several biomarkers have been proposed in the literature for diagnosis in patients with these tumors.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Athar A,

Keywords: Biochemical markers, PNETs, Better prognosis,

#1857 Association between Neuroendocrine Tumors (NETs) Biomarkers and Tumor Burden Based on Total 68Ga-DOTATATE-Avid Tumor Volume (TV) Measurements

Introduction: No study has yet assessed the utility of biochemical biomarkers for evaluating NET burden using 68Ga-DOTATATE PET/CT.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Tirosh A, Papadakis G, Millo C, Sadowski S, Herscovitch P,

Keywords: PET burden,

#1853 24 Hour Urinary 5-Hydroxyindoleacetic Acid (5HIAA) and Vasoactive Intestinal Peptide (VIP) Doubling-Times (DTs) Predict Disease-Specific Mortality (DSM) in Patients with Neuroendocrine Tumors (NETs)

Introduction: New clinical prognostic tools are needed in order to select patients with NETs that are at higher risk of DSM. Biochemical biomarker DT is used clinically for prognosis prediction in several solid malignancies

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Tirosh A

Authors: Tirosh A, Nilubol N, Patel D, Kebebew E,

Keywords: doubling time, biomarker, prognosis,

#899 Evaluation of the Clinical Utility of Plasma Biomarkers in Diagnosis of Neuroendocrine Tumors

Introduction: Neuroendocrine tumors (NETs) are rare cancers that usually develop in the gastroenterohepatic system. Diagnostic workup of these tumors includes measurement of plasma levels of marker peptides. Clinical experience suggests that these markers may be misleading if used before histological or imaging evidence of a NET is available.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Lunberg-Adams M

Authors: Lunberg-Adams M, James A, Perros P,

Keywords: chromogranin A, neurokinin A, pancreatic polypeptide, neuroendocrine tumor diagnosis,